Drug intelligence / Profile preview

PB127

Development stage: Phase 3
Lead developer: Point Biomedical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

PB127 is an investigational ultrasound contrast agent developed for myocardial perfusion imaging, particularly in patients with suspected or known coronary artery disease. It consists of intravenously administered microspheres that enhance the visualization of blood flow during ultrasound imaging procedures. The agent is effective for intermittent harmonic power Doppler imaging and has been studied as a potential first FDA-approved contrast agent specifically for myocardial perfusion assessment. Clinical studies have also evaluated its safety profile in patients with varying pulmonary hemodynamics and its use alongside pharmacologic stress agents such as dipyridamole[1][2][3][5][7].

Brand names: CardioSphere
Other names: CardioSpherePB-127PB127PB 127

Beyond the preview

Go deeper on PB127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB127.

Explore the full profile